Myriad Genetics Inc (MYGN)
Profitability ratios
Return on sales
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Jun 30, 2020 | Jun 30, 2019 | |
|---|---|---|---|---|---|
| Gross profit margin | -0.30% | 13.46% | 27.41% | -8.60% | 25.18% |
| Operating profit margin | -34.53% | -20.82% | -22.52% | -36.91% | 0.90% |
| Pretax margin | -35.18% | -20.82% | -6.75% | -35.55% | 0.02% |
| Net profit margin | -35.32% | -16.59% | -3.22% | -31.78% | 0.55% |
Myriad Genetics, Inc.'s profitability ratios have shown fluctuations over the past five years. The gross profit margin has generally been in a healthy range, declining slightly from 76.38% in June 2019 to 68.64% in December 2023. This indicates that the company has been effective in controlling its direct production costs.
However, the operating profit margin and pre-tax margin have been negative in recent years, indicating that the company's operating expenses and other costs are high relative to its revenue. The trend shows a slight improvement in operating profit margin from -21.11% in June 2020 to -19.20% in December 2023.
The net profit margin, which reflects the company's overall profitability after all expenses have been deducted, has also shown fluctuations over the years. It decreased significantly from 0.54% in June 2019 to -34.96% in December 2023, suggesting that Myriad Genetics, Inc. has been experiencing losses in recent periods.
Overall, Myriad Genetics, Inc. faces challenges in improving its operational efficiency and reducing its costs to enhance its profitability. Further analysis of the company's cost structure and revenue generation strategies may be necessary to address these issues and drive towards sustainable profitability.
Return on investment
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Jun 30, 2020 | Jun 30, 2019 | |
|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -22.45% | -11.73% | -14.42% | -16.50% | 0.49% |
| Return on assets (ROA) | -22.97% | -9.34% | -2.06% | -14.20% | 0.29% |
| Return on total capital | -31.56% | -15.51% | -5.22% | -18.59% | 0.92% |
| Return on equity (ROE) | -33.62% | -12.64% | -2.81% | -21.73% | 0.42% |
Myriad Genetics, Inc.'s profitability ratios have shown significant fluctuations over the past five years.
The Operating Return on Assets (Operating ROA) has been negative in all years, ranging from -12.61% to -9.59%. This indicates that the company is not generating positive operating income relative to its assets.
The Return on Assets (ROA) has also been negative in most years, with a significant decline in profitability in 2023, reaching -22.97%. This suggests that the company is not efficiently utilizing its assets to generate profits.
The Return on Total Capital has also been negative throughout the years, showing a downward trend from -11.80% to -17.60%. This implies that the company's overall capital investments have not been generating positive returns.
Furthermore, the Return on Equity (ROE) has been negative across all years, with the lowest figure recorded in 2023 at -33.62%. This indicates that the company's profitability in relation to shareholder equity has been consistently poor.
Overall, the profitability ratios of Myriad Genetics, Inc. reflect a concerning trend of declining profitability and inefficiency in utilizing assets and capital.